CN101138579B - Astragalus root fermentation liquor and uses thereof - Google Patents
Astragalus root fermentation liquor and uses thereof Download PDFInfo
- Publication number
- CN101138579B CN101138579B CN2007102013631A CN200710201363A CN101138579B CN 101138579 B CN101138579 B CN 101138579B CN 2007102013631 A CN2007102013631 A CN 2007102013631A CN 200710201363 A CN200710201363 A CN 200710201363A CN 101138579 B CN101138579 B CN 101138579B
- Authority
- CN
- China
- Prior art keywords
- fermentation
- astragalus root
- hypoxia
- fermentation liquor
- root fermentation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000855 fermentation Methods 0.000 title claims abstract description 42
- 230000004151 fermentation Effects 0.000 title claims abstract description 41
- 229940107666 astragalus root Drugs 0.000 title claims description 16
- 239000003814 drug Substances 0.000 claims abstract description 45
- 241000233866 Fungi Species 0.000 claims abstract description 22
- 239000007788 liquid Substances 0.000 claims abstract description 16
- 206010021143 Hypoxia Diseases 0.000 claims abstract description 13
- 239000003146 anticoagulant agent Substances 0.000 claims abstract description 8
- 229940127219 anticoagulant drug Drugs 0.000 claims abstract description 7
- 235000013305 food Nutrition 0.000 claims abstract description 6
- 235000015097 nutrients Nutrition 0.000 claims abstract description 4
- 239000009636 Huang Qi Substances 0.000 claims description 26
- 239000006228 supernatant Substances 0.000 claims description 14
- 235000001674 Agaricus brunnescens Nutrition 0.000 claims description 13
- 230000001580 bacterial effect Effects 0.000 claims description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000012153 distilled water Substances 0.000 claims description 9
- 238000002360 preparation method Methods 0.000 claims description 9
- 235000015099 wheat brans Nutrition 0.000 claims description 6
- 239000000047 product Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 3
- 239000010440 gypsum Substances 0.000 claims description 3
- 229910052602 gypsum Inorganic materials 0.000 claims description 3
- 238000011081 inoculation Methods 0.000 claims description 3
- 239000002054 inoculum Substances 0.000 claims description 3
- 235000007685 Pleurotus columbinus Nutrition 0.000 claims 2
- 240000001462 Pleurotus ostreatus Species 0.000 claims 2
- 235000001603 Pleurotus ostreatus Nutrition 0.000 claims 2
- 230000010100 anticoagulation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 20
- 239000000463 material Substances 0.000 abstract description 16
- 235000006533 astragalus Nutrition 0.000 abstract description 11
- 230000012010 growth Effects 0.000 abstract description 10
- 241001465754 Metazoa Species 0.000 abstract description 9
- 241001061264 Astragalus Species 0.000 abstract description 8
- 238000012545 processing Methods 0.000 abstract description 8
- 238000002474 experimental method Methods 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 241000293268 Astragalus chinensis Species 0.000 abstract 3
- 206010002660 Anoxia Diseases 0.000 abstract 2
- 235000010110 Astragalus glycyphyllos Nutrition 0.000 abstract 2
- 230000002429 anti-coagulating effect Effects 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 17
- 241000894006 Bacteria Species 0.000 description 14
- 230000000694 effects Effects 0.000 description 12
- 238000003304 gavage Methods 0.000 description 9
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- 238000009395 breeding Methods 0.000 description 7
- 230000001488 breeding effect Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 206010053567 Coagulopathies Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000035602 clotting Effects 0.000 description 6
- 239000012530 fluid Substances 0.000 description 6
- 230000000050 nutritive effect Effects 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 230000004083 survival effect Effects 0.000 description 6
- 210000004233 talus Anatomy 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 5
- 230000000740 bleeding effect Effects 0.000 description 5
- 239000000470 constituent Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 241000045403 Astragalus propinquus Species 0.000 description 4
- 229920002488 Hemicellulose Polymers 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000007954 hypoxia Effects 0.000 description 4
- 239000001814 pectin Substances 0.000 description 4
- 229920001277 pectin Polymers 0.000 description 4
- 235000010987 pectin Nutrition 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- -1 xylogen Polymers 0.000 description 4
- 239000004382 Amylase Substances 0.000 description 3
- 108010065511 Amylases Proteins 0.000 description 3
- 102000013142 Amylases Human genes 0.000 description 3
- 244000020518 Carthamus tinctorius Species 0.000 description 3
- 235000003255 Carthamus tinctorius Nutrition 0.000 description 3
- 108010059892 Cellulase Proteins 0.000 description 3
- 244000234623 Coprinus comatus Species 0.000 description 3
- 235000004439 Coprinus comatus Nutrition 0.000 description 3
- 244000302512 Momordica charantia Species 0.000 description 3
- 235000009811 Momordica charantia Nutrition 0.000 description 3
- 235000009812 Momordica cochinchinensis Nutrition 0.000 description 3
- 235000018365 Momordica dioica Nutrition 0.000 description 3
- 108010059820 Polygalacturonase Proteins 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 235000019418 amylase Nutrition 0.000 description 3
- 229940106157 cellulase Drugs 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 229940059442 hemicellulase Drugs 0.000 description 3
- 108010002430 hemicellulase Proteins 0.000 description 3
- 239000004615 ingredient Substances 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 208000028867 ischemia Diseases 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 244000158441 Pleurotus sajor caju Species 0.000 description 2
- 235000004116 Pleurotus sajor caju Nutrition 0.000 description 2
- 240000006794 Volvariella volvacea Species 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000002785 anti-thrombosis Effects 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000002950 deficient Effects 0.000 description 2
- 230000000857 drug effect Effects 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 238000000227 grinding Methods 0.000 description 2
- 230000001077 hypotensive effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000008558 metabolic pathway by substance Effects 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 231100000572 poisoning Toxicity 0.000 description 2
- 230000000607 poisoning effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000029058 respiratory gaseous exchange Effects 0.000 description 2
- 229930000044 secondary metabolite Natural products 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000000528 statistical test Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- ODINCKMPIJJUCX-UHFFFAOYSA-N Calcium oxide Chemical compound [Ca]=O ODINCKMPIJJUCX-UHFFFAOYSA-N 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 101710145505 Fiber protein Proteins 0.000 description 1
- 208000022461 Glomerular disease Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940088623 biologically active substance Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 231100000852 glomerular disease Toxicity 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100001261 hazardous Toxicity 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000003715 nutritional status Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000003836 peripheral circulation Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 238000012805 post-processing Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 239000002893 slag Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940099259 vaseline Drugs 0.000 description 1
- 239000002912 waste gas Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Landscapes
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the art of Chinese medicine processing and bio-fermentation, in particular to a fermentation method of Chinese milkvetch and an application of fermented product through the method. The invention makes the fermentation of Chinese milkvetch by taking large edible fungus as the starting fungus of Chinese medicine fermentation, Chinese milkvetch as the main material of fermentation culture medium and adding a small amount of necessary nutrients for fungus production and growth. Animal experiment show that the fermented milkvetch liquid has the anti-anoxia and anticoagulant effect. The application of the invention refers to the fermented milkvetch liquid obtained through the method can be applied in preparing anti-anoxia and anticoagulant medicine as well as corresponding health products and food.
Description
Technical field:
The present invention relates to Chinese medicine processing and biological fermentation field, the particularly fermentation process of Chinese medicine astragalus, and the application of the tunning that obtains by this method.
Background technology:
The Radix Astragali, the root for leguminous plants Radix Astragali Astragalus membranaceus (Fisch.) Bge. and Inner Mongolia Astragalis A.membranaceus Bge.varmongholicus (Bge.) Hsiao originates in the ground such as northeast, northwest, North China
[1]The Radix Astragali is classified as top grade by Shennong's Herbal, be one of common medicine, is important Qi-tonifying drug, and the admittedly effect of table, promoting pus discharge and tissue regeneration by strengthening QI, sharp water detumescence of tonifying Qi Kaiyang, beneficial stomach is arranged
[2]Pharmacological evaluation proves that the Radix Astragali has antibiotic, the enhancing body immunological competence, and the expansion peripheral blood vessel is promoted peripheral circulation, improves the effects such as local nutritional status
[1]In addition, the Radix Astragali still has hypoxia tolerance, antifatigue, and anti-inflammatory, antitumor, the effects such as diuresis
[3-6]Astragalus polysaccharides can make animal spleen increase the hyperplasia of spleen entoplasm; Radix Astragali γ-aminobutyric acid has hypotensive effect; Astragaloside has antithrombotic to form and hypotensive effect, and the cAMP in plasma amount that can raise is synthetic with the DNA that promotes the mouse Liver Regeneration
[1,7]
The development of Chinese medicine has long history with application, is the rarity of the Chinese nation, and very important effect is arranged in the social development process.Yet, no matter be the traditional Chinese medicine preparation method of China, or the extraction process of modern large enterprises, all be to adopt poach or a large amount of organic solvents to manage have the composition of pharmaceutical use and structural material without pharmaceutical use to separate in Chinese medicine, its limitation is that extracts active ingredients is insufficient or only for the extraction of certain or some compositions, and curative effect is reduced, and limited natural resources of Chinese medicinal materials is wasted in a large number, also can produce a large amount of residual residue and hazardous solvent simultaneously, environment is worked the mischief.Therefore, utilize the method for biological fermentation that Chinese medicine is processed, become one of study hotspot of the modernization of Chinese medicine
[8]Herb fermenting is the ability of utilizing the powerful decomposition and inversion material of microorganism, produces abundant secondary metabolite, thereby reaches concentrated effective constituent, changes the property of medicine, improves curative effect, reduces toxic side effect, enlarges the purpose of indication.Because herb fermenting is in the unique advantage that has aspect the modernization of cmm exploitation, so development prospect is wide.
Yet see that with regard to present existing technology herb fermenting research also exists some defectives and deficiency:
At first, from fermention medium, the research that has is exactly merely in order to cultivate medicinal fungi, does not add traditional Chinese medicine ingredients in the fermention medium; The interpolation that has traditional Chinese medicine ingredients, also just add as auxiliary material.Be 200510068284.9 such as number of patent application, name is called the patent of " a kind of coprinus comatus liquid fermentation process and leavened prod that adds balsam pear ", its processing method is exactly for the bacterial classification that sets out with coprinus comatus, in liquid fermentation medium, added a small amount of Chinese medicine balsam pear, its objective is mass liquid cultivation coprinus comatus, adding the Chinese medicine balsam pear then is in order to improve the activity of fermented liquid.And for example have the people to add a certain amount of Chinese medicine astragalus in fermention medium, access is cultured liquid Ganderma lucidum strain in advance, and after fermentation after a while, by measuring the content of ganoderan, the research Radix Astragali is on producing the impact of ganoderan
[9]Above-mentioned research places dominant position with medicinal fungi, and Chinese medicine then lays under tribute, and take medicinal fungi as standard, and does not consider Chinese medicine in the fermention medium on the drug effect of tunning detects.
The characteristics such as next from the Chinese medicine fermented bacterium, is lacked because bacterium has the breeding cycle, and is of a great variety, and metabolic way is various, thus there are many researchs to adopt bacteriums as the bacterial classification that sets out of herb fermenting, and herb fermenting has been obtained good effect.Yet most of bacterium as fermented bacterium is had relatively high expectations to nutritive substance because of it, and Chinese medicine is limited to the nutritive substance that bacterial growth provides.Some researchs can be carried out smoothly for the growth that is beneficial to fermented bacterium makes fermentation, the nutritive substance that in the herb fermenting substratum, has added more promotion bacterial growth breeding, so just reduced the relative proportion of Chinese medicine in fermention medium, reduce the metabolism of bacterium to Chinese medicine, and then affected the ferment effect of Chinese medicine.Be 03117590.2 such as number of patent application, name is called " Synergistic safflower soluble suppository preparation " patent, its fermentation bacterial classification that sets out is exactly a bacillus, and it has added except safflower nearly six kinds nutritive substance in the fermention medium of Chinese medicine safflower, to promote the growth and breeding of bacterial classification.The production cost that so not only raise, and increased difficulty and program for the subsequent disposal of tunning.
Large edible fungus such as flat mushroom, needle mushroom, straw mushroom, Pleurotus sajor-caju, mushroom, two born of the same parents mushrooms etc., as appetizing nutritive foodstuff on people's dining table, do not have pharmaceutical use, its biologically active substance that produces in growth and breeding can not have a negative impact to the Study on mechanism of Chinese medicine in the substratum.It is strong that the mycelium of large edible fungus has the growth and breeding ability, require low to nutritive substance, the advantage that is easy to cultivate, and in the growth and breeding process, can produce abundant enzyme system, such as cellulase, hemicellulase, polygalacturonase, amylase etc., the decomposition with materials such as stronger lignocellulose, hemicellulose, xylogen, pectin utilizes ability.Utilize these characteristics of large edible fungus, it can be used to Chinese medicine is fermented.
For the defective of prior art, the present invention has carried out fermentative processing take the large edible fungus flat mushroom as example to Chinese medicine astragalus.
In existing document, not yet find with large edible fungus as herb fermenting set out bacterial classification, take Chinese medicinal materials as the fermention medium major ingredient, utilize the abundant cellulase of large edible fungus, hemicellulase, polygalacturonase, amylase etc., the materials such as lignocellulose, hemicellulose, xylogen, pectin in the Chinese medicinal materials are decomposed, the activeconstituents of Chinese medicinal materials fully is released in the research of aspect in the fermentation aqueous solution.
Reference:
(1). Su Zhongwu, Qiao Chuanzhuo. pharmacognosy. Shanghai: press of Shanghai Medical Univ, 1989.pp129-132.
(2). Chengdu Traditional Chinese Medical College. pharmacognosy. Shanghai: Shanghai science tech publishing house, 1978.pp288-289.
(3). Zhu Huaye, Piao Long. the research of Radix Astragali extract anti-inflammatory, analgesia, hypoxia tolerance and antifatigue effect. the time precious traditional Chinese medical science traditional Chinese medicines, 2007,18 (5): 1156-1157.
(4). Li Weiping, bright, Zhang Yan, Wang Cuifang, Fang Ming, Liu Xiaoying. the experimental study of astragalus polysaccharides resisting oxygen lack. Medical University Of Anhui's journal, 1995,30 (3): 184-185.
(5). Quan Hongxun. Astragalus membranaceus is on the impact of Cyclophosphamide Antitumor Activity and toxicity. Chinese medicinal materials, 1995,18 (7): 356-358.
(6). week admires, Li Rongheng. and the Radix Astragali is to the regulating effect of renal glomerular disease substance metabolism disorder. herbal medicine, 1999,30 (5): 386-388.
(7). height is built, Xu Xianxiang, Xu Xianjun, Ni Shoudong. Radix Astragali total saponins anti-thrombosis function experimental study. Chinese patent medicine, 2002,24 (2): 116-118.
(8). WuBing Xin, Niu Jijiang, Sun Xiaolin, Dong Lishan. the herb fermenting pharmaceutical technology. Shandong journal of traditional Chinese medicine, 2001,20 (3): 179-180.
(9). Wang Yuhong, fourth Double Ninth Festival, Xu Peng, Zhang Kechang. Chinese medicine astragalus is on the impact of fermentative production ganoderan. food and biotechnology journal, 2005,24 (2): 38-40.
Summary of the invention:
The objective of the invention is to utilize large edible fungus, such as flat mushroom, needle mushroom, straw mushroom, Pleurotus sajor-caju, mushroom, two born of the same parents mushrooms etc., Mierocrystalline cellulose in the Chinese medicinal materials, hemicellulose, xylogen, pectin etc. are utilized ability without the decomposition of pharmaceutical use material, main component in take Chinese medicinal materials as substratum is mixed with the liquid nutrient medium of edibility fungal growth, ferments under suitable fermentation condition and suitable fermentation period.In this process, in the Radix Astragali without the material of pharmaceutical use by the enzyme system that large edible fungus produced, such as cellulase, hemicellulase, polygalacturonase, amylase etc. degraded, effective constituent is able to abundant release.On the other hand, under the metabolism of large edible fungus, some effective constituent in the Radix Astragali is as precursor, form novel compound, perhaps a large amount of secondary metabolites of in the growth and breeding process, producing of large edible fungus and some composition in Radix Astragali formation novel compound that occurs to interact.So just reach in the aqueous solution effective constituent in the abundant releasing Chinese medicine material or produced the new purpose that the pharmaceutical use composition is arranged.
The present invention relates to utilize the method for large edible fungus fermented tcm material, and the application of the tunning that obtains by this method.Concrete technology contents of the present invention is as follows:
Radix Astragali fermentation process is characterized in that: utilize the large edible fungus Radix Astragali that ferments.
The used fermented bacterium of the present invention is the large edible fungus flat mushroom.Fermention medium moiety (unit: g/L): the Radix Astragali 30～90, wheat bran 10～20, gypsum 0.5～1.5, distilled water.Astragalus membranaceus powder is broken to 60 purpose powder; The wheat bran liquor filters to get filtrate; Terra alba is broken to 60 purpose powder.500mL triangular flask packing substratum 120～170mL, inoculation liquid fermented bacterium behind the autoclaving, inoculum size is 5～15%, shaking table shaking culture under 25～28 ℃, 130～180r/min condition, incubation time is 6～10d, obtains astragalus root fermentation liquor.Astragalus root fermentation liquor through 3500～5000r/min centrifugal supernatant liquor, this supernatant liquor can be directly uses as food, healthcare products and medicine, perhaps for the preparation of the raw material of food, healthcare products and medicine.
The present invention adopts the method for shaking flask to carry out, if amplify production, can adopt the modes such as groove processing, post processing, tank processing, fermentor tank processing and microbial immobilized processing to carry out the Radix Codonopsis fermentative processing according to ultimate principle of the present invention, this be that the researcher in this field is to understand.
The present invention can make the drug effect of Chinese medicine astragalus be enhanced, because the present invention adopts edible fungus as the bacterial classification that sets out of fermentation, can be with part in the Chinese medicine astragalus without the substance metabolism utilization such as the Mierocrystalline cellulose of pharmaceutical use, hemicellulose, xylogen, pectin or change into micromolecular sugar etc.; And the content of the biologically active substances such as small protein, total free aminoacids is increased greatly; Active substance fully discharges; Effective constituent can be fit to absorption of human body more, improves curative effect.In addition, the present invention can not produce waste gas, waste liquid etc. in whole process, compare the solid slag of generation with the traditional Chinese medicine working method still less, is conducive to reduce the harm to environment.Fermentation process provided by the invention is suitable for other folk prescriptions or herbal mixture equally, for advancing Chinese medicine development, raising modernization of Chinese medicine level to be significant.
Embodiment:
Embodiment one: the preparation of astragalus root fermentation liquor.
The used fermented bacterium of the present invention is the large edible fungus flat mushroom.Fermention medium moiety (unit: g/L): the Radix Astragali 30～90, wheat bran 10～20, gypsum 0.5～1.5, distilled water.Astragalus membranaceus powder is broken to 60 purpose powder; The wheat bran liquor filters to get filtrate; Terra alba is broken to 60 purpose powder.500mL triangular flask packing substratum 120～170mL, inoculation liquid fermented bacterium behind the autoclaving, inoculum size is 5～15%, shaking table shaking culture under 25～28 ℃, 130～180r/min condition, incubation time is 6～10d, obtains astragalus root fermentation liquor.Astragalus root fermentation liquor through 3500～5000r/min centrifugal supernatant liquor, this supernatant liquor can be directly uses as food, healthcare products and medicine, perhaps for the preparation of the raw material of food, healthcare products and medicine.
Embodiment two: the anti-hypoxia of Radix Astragali fermented supernatant fluid is active.
Laboratory animal: healthy male mice in kunming, body weight 20 ± 2g.
Experimental agents: the supernatant liquor according to embodiment 1 preparation is mixed with large, medium and small three concentration doses, and its original crude drug content is respectively 0.412g/mL, 0.206g/mL and 0.052 g/mL.Not connecing the original crude drug content of bacterial classification control group supernatant liquor is 0.206g/mL.The original crude drug content of decocting liquid control group supernatant liquor is 0.206g/mL.
Experimentation on animals:
1., Ischemia Injury in Brain anoxic experiment:
60 mouse are divided into 6 groups at random, 10 every group, be divided into Radix Astragali fermentation and organize large, medium and small 3 dosage, the Radix Astragali does not connect the bacterium control group, Radix Astragali decocting group and blank group, the blank group gives sterilized water.Every 10g mouse stomach administration 0.2ml, be administered once every day, continuously gavage 10d.1h after the last gavage breaks end at mouse ears line place fast with scissors, behind the stopwatch immediate record mouse broken end to the stand-by time of breathing of dehiscing.
2., normal pressure hypoxia tolerance experiment:
Animal grouping and gavage method are the same.1h after the last gavage puts into respectively the 250ml port grinding bottle (putting 1 mouse for every bottle) that fills the 7g sodica calx with each group mouse, smears bottleneck with Vaseline, cover tightly, make it air tight, immediately timing, until mouse breathing stops the record survival time of mouse in airtight port grinding bottle.
3., Sodium Nitrite poisoning anoxic experiment:
Animal grouping and gavage method are the same.1h after the last gavage, each treated animal record the mouse survival time all by 220mg/kg abdominal injection sodium nitrite solution.
Experimental data represents that with x ± s statistical test adopts SPSS13.0 software to process.
Experimental result
The anti-hypoxia activity of table 1 Radix Astragali fermented supernatant fluid (x ± s)
| Group | Dosage g/kg/d | Ischemia Injury in Brain anoxic broken end expiration t/s | Normobaric hypoxia survival t/min | Sodium Nitrite poisoning survival t/min |
| Distilled water contrast decocting does not connect dosage fermentation heavy dose in the low dose of fermentation of bacterium control fermentation | -4.124.121.044.128.24 | 18.9±1.720.3±1.5 *19.3±2.020.2±1.220.6±1.1 *20.9±1.6 ** | 19.7±3.323.2±3.1 *19.8±2.922.9±5.024.1±6.3 *25.0±3.7 ** | 15.2±2.217.0±2.615.8±2.416.5±2.717.8±2.7 *18.2±3.0 * |
Table 1 shows, compare with the distilled water control group, the large dose Astragalis fermented liquid can break end expiratory duration and normobaric hypoxia mouse survival time by significant prolongation (P＜0.01) Ischemia Injury in Brain hypoxia mice, middle dosage take second place (P＜0.05), low dose can make time lengthening, but not statistically significant; Compare with the distilled water control group, big or middle dosage astragalus root fermentation liquor can obviously prolong (P＜0.05) mouse Sodium Nitrite and poison the survival time, and low dose can also make time lengthening, but not statistically significant.
Embodiment three: the anticoagulant active of Radix Astragali fermented supernatant fluid:
Laboratory animal, Experimental agents, animal grouping, gavage method etc. are all with embodiment two.
1., Radix Astragali fermented supernatant fluid affects (slide method) to clotting time of mice:
1h after the last gavage, mouse tail is got blood, detects and record drop of blood from flowing out to the time that fiber protein yarn occurs, is the clotting time.
2., Radix Astragali fermented supernatant fluid is on the impact in mouse bleeding time:
1h after the last gavage fixes mouse, with profit cut cross-section from Mouse Tail-tip 1cm after, treat that blood begins to clock when automatically overflowing, suck tail point drop of blood every 20s with filter paper, until blood naturally stop to flow out till (when filter paper is inhaled without blood), the record bleeding time.
Experimental data represents that with x ± s statistical test adopts SPSS13.0 software to process.
Experimental result
The anticoagulant active of table 2 Radix Astragali fermented supernatant fluid (x ± s)
| Group | Dosage g/kg/d | Clotting time t/min | Bleeding time t/min |
| Distilled water contrast decocting does not connect dosage fermentation heavy dose in the low dose of fermentation of bacterium control fermentation | -4.124.121.044.128.24 | 4.2±1.35.2±0.8 *4.1±1.45.5±0.6 *6.8±0.9 **△7.5±0.8 **△ | 18.7±3.222.5±2.6 *19.5±2.622.1±3.3 *23.0±3.4 *23.7±4.4 ** |
Table 2 shows, compares with the distilled water control group, and big or middle dosage astragalus root fermentation liquor can significant prolongation (P＜0.01) clotting time of mice, low dose take second place (P＜0.05).Compare with the distilled water control group, the large dose Astragalis fermented liquid can significant prolongation (P＜0.01) the mouse bleeding time, in, low dose take second place (P＜0.05).
Table 2 shows, compares with the decocting group, big or middle dosage astragalus root fermentation liquor energy significant prolongation (P＜0.01) clotting time of mice, though low dose can prolong the clotting time, difference is not remarkable.Compare with the decocting group, big or middle dosage astragalus root fermentation liquor can prolong the mouse bleeding time, but difference not significantly (P＞0.05).
Claims (3)
1. preparation method with astragalus root fermentation liquor of anti-hypoxia and anticoagulant efficacy is characterized in that:
A. produce bacterial strain and be the edible fungus flat mushroom (
Pleurotus Ostreatus );
B. every l L fermention medium consists of the 30-90g Radix Astragali, the 10-20g wheat bran, and 0.5-1. 5g gypsum, distilled water, wherein the wheat bran liquor gets filtrate;
C. with flat mushroom (
Pleurotus Ostreatus ) the liquid fermenting bacterial classification inoculation is in the 500ml triangular flask that the 120ml-170ml fermention medium is housed, inoculum size 5%-15% is 25 in temperature
oC-28
oC cultivated 6-10 days under the condition of 130-180rpm, can obtain nutrient solution;
D. with above-mentioned nutrient solution centrifugal supernatant liquor that obtains under rotating speed 3500-5000rpm, namely obtain astragalus root fermentation liquor.
2. astragalus root fermentation liquor with anti-hypoxia and anticoagulant efficacy, it is characterized in that: this fermented liquid is to prepare through a kind of preparation method with astragalus root fermentation liquor of anti-hypoxia and anticoagulant efficacy as claimed in claim 1.
3. the as claimed in claim 2 a kind of application of astragalus root fermentation liquor in preparation anti-hypoxia and anticoagulation food, healthcare products or medicine with anti-hypoxia and anticoagulant efficacy.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007102013631A CN101138579B (en) | 2007-08-15 | 2007-08-15 | Astragalus root fermentation liquor and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2007102013631A CN101138579B (en) | 2007-08-15 | 2007-08-15 | Astragalus root fermentation liquor and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101138579A CN101138579A (en) | 2008-03-12 |
| CN101138579B true CN101138579B (en) | 2013-03-20 |
Family
ID=39190788
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007102013631A Expired - Fee Related CN101138579B (en) | 2007-08-15 | 2007-08-15 | Astragalus root fermentation liquor and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101138579B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102643771B (en) * | 2012-05-09 | 2014-10-29 | 中国农业科学院兰州畜牧与兽药研究所 | Fermentation medium for extracting astragalus polysaccharides |
| CN104611232B (en) * | 2014-12-16 | 2018-03-06 | 湖南新汇制药股份有限公司 | The application of a kind of bioconversion mycelium and its extract in anticoagulation medicine is prepared |
| KR101799424B1 (en) * | 2015-05-20 | 2017-11-20 | 주식회사 코시스바이오 | Astragalus membranaceus Fermentation product and its manufacturing method |
| CN116159114B (en) * | 2023-03-16 | 2023-11-28 | 上海交通大学 | Fermentation preparation process of astragalus, dendrobium and fructus forsythiae resolving beverage and product |
-
2007
- 2007-08-15 CN CN2007102013631A patent/CN101138579B/en not_active Expired - Fee Related
Non-Patent Citations (2)
| Title |
|---|
| 杨志荣.灵芝与中药共发酵产物的药理学初步研究.《2006中国微生物学会第九次全国会员代表大会暨学术年会论文摘要集》.2006,253. |
| 灵芝与中药共发酵产物的药理学初步研究;杨志荣;《2006中国微生物学会第九次全国会员代表大会暨学术年会论文摘要集》;20061231;253 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101138579A (en) | 2008-03-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101138576B (en) | Codonopsis pilosula fermentation liquor and uses thereof | |
| CN100494341C (en) | Huishuhua fermentation preparation process using Chinese herb medicine as medium | |
| CN105053593A (en) | Traditional Chinese medicine residues prepared poultry feed additive and preparation method thereof | |
| CN109315586B (en) | Preparation method and application of fermented Chinese herbal medicine biological feed for ruminants | |
| CN102217708B (en) | Novel environment-friendly feed additive and preparation method thereof | |
| CN104623122B (en) | A kind of biological agent and preparation method thereof with anti-fatigue effect | |
| CN106581083A (en) | Extraction method for ganoderma lucidum components, biological feed and preparation method thereof | |
| CN104068379B (en) | A kind of health care oral liquid | |
| CN1321186C (en) | Chinese traditional medicine containing glycosides transformed by ferment of microbe, and method for producing relevant aglycone preparation | |
| CN103976351B (en) | A kind of health food of develop immunitypty improving water flood and two-step fermentation preparation method thereof | |
| CN103190547B (en) | Chinese herbal medicine feed additive for effectively controlling comprehensive respiratory diseases of pigs | |
| CN104195052B (en) | A kind of Hericium erinaceus (Bull. Ex Fr.) Pers. filament and breeding method thereof | |
| CN104152491A (en) | Fermented Radix Astragali preparation method, and method for extracting total saponins of fermented Radix Astragali | |
| CN101138579B (en) | Astragalus root fermentation liquor and uses thereof | |
| CN105176844B (en) | A kind of Chinese medicine of Inonotus obliquus or the two-way solid fermentation method of Chinese medicine slag | |
| CN103146592A (en) | Microzyme converting ginsenoside Rb1 to generate Rd and application thereof | |
| CN103948023B (en) | The health food of a kind of develop immunitypty and improving water flood and two-step fermentation preparation method thereof | |
| CN103932181B (en) | A kind ofly to release the pressure and the functional food of Improving memory and two-step fermentation preparation method thereof | |
| CN104000192B (en) | A kind of functional food and two-step fermentation preparation method thereof releasing the pressure and regulate stomach | |
| CN102676627A (en) | Microbial fermentation extraction method of total arasaponin | |
| Luo et al. | Recycling utilization of Chinese medicine herbal residues resources: systematic evaluation on industrializable treatment modes | |
| CN105368695A (en) | Fermented vinegar with poria cocos and propolis and method for manufacturing fermented vinegar | |
| CN103932179B (en) | A kind of health food and two-step fermentation preparation method thereof releasing the pressure and protect liver | |
| CN103932180A (en) | Pressure-relieving and anti-fatigue health-care food and two-step fermentation preparation method thereof | |
| CN106497795A (en) | A kind of Cordyceps funguss seed culture medium containing Fructus Lycii and its application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: LANZHOU UNIVERSITY Free format text: FORMER OWNER: LI HONGYU Effective date: 20140106 Free format text: FORMER OWNER: LANZHOU UNIVERSITY Effective date: 20140106 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20140106 Address after: 730000 No. 222, Tian Shui Road, Chengguan District, Gansu, Lanzhou Patentee after: LANZHOU University Address before: 730000 No. 222, Tian Shui Road, Chengguan District, Gansu, Lanzhou Patentee before: Li Hongyu Patentee before: Lanzhou University |
|
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130320 |